DBV Technologies enrols first patient in Phase III peanut allergy trial
French biopharmaceutical firm DBV Technologies has started patient enrolment in a Phase III EPITOPE clinical trial of Viaskin Peanut to treat peanut allergy in young children.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Allergy | Allergy & Immunology | Child Development | Children | Clinical Trials | France Health | Peanuts